



RIVKINCENTER
women's lives. our passion.

PILOT STUDY AWARDS *in ovarian cancer research* **\$75,000 Two-Year Awards** **Request for Applications**

Pilot Study Award Overview

The Rivkin Center is announcing funds for Pilot Study Awards to be allocated based on scientific merit. Pilot Study Awards support investigator-initiated projects in all areas of ovarian cancer research. In addition, projects designed to analyze data from already funded clinical trials will be considered. The two-year awards will provide a total of \$75,000 in funding. *Funds are for direct costs only; institutional overhead and indirect costs will not be included in the award.*

Applicants may budget for salary support, materials, supplies, consumables, travel costs for scientific meetings, and other expenses as justified. Budget and budget justification must be included with the application.

Funding priority will be given to proposals that are:

- *Innovative*
- *Multidisciplinary*
- *Likely leading to submission of grant applications for independently funded investigations*
- *Conveying translational research potential*

Eligibility

Investigators at the assistant, associate, or full professor level (or equivalent) are eligible to apply, subject to guidelines of the applicant's home institution.

Requirements upon funding

Interim scientific and financial reports must be provided within 30 days following the first anniversary of the start date of the award. Final scientific and financial reports must be provided within 90 days after the completion of the funding period. In addition to submitting all final reports and annual updates, award recipients are highly encouraged to present at the next forthcoming Rivkin Center-AACR Symposium following the completion of funding. Award recipients are encouraged to use results to publish findings and develop full-scale funding applications to national agencies.

Application Format and Instructions

Applicants should submit a proposal application to the Rivkin Center via proposalcentral.com, including applicant/PI and institution contact information, scientific proposal, budget information, biosketch, other support, organizational assurances, and scientific and lay abstracts.

Scientific Proposal

The Scientific Proposal should be no more than five pages in length addressing each of the following areas: Specific Aims, Background and Significance, Preliminary Results (if available), and Research Design and Methods (Arial or other acceptable font, 11 point minimum, 8.5" x 11" paper, 0.5" margins). All tables, figures, and images must fit within the five-page limit and be legible. References should be included and are not counted as part of the five-page limit. Additional materials (e.g. published papers, submitted manuscripts, letters of support, summary of facilities and resources, etc.) will not be considered.

Application Submission

All application materials should be submitted through proposalcentral.com by the application **due date (December 1, 2023, 2 PM Pacific Time/ 5 PM Eastern Time)**. Applicants who do not already have an account in proposalCENTRAL must register for an account prior to beginning application. Once completed, the application must be validated to ensure all materials have been submitted. Signature pages must include a wet signature or a secure digital signature from the authorized institutional official.

More Information

Visit proposalcentral.com or rivkin.org for the latest Guidelines. Questions may be directed to Jackie Lang, PhD at Jackie.Lang@rivkin.org or (206) 584-2357.

The Rivkin Center for Ovarian Cancer is an independent 501(c)(3) non-profit organization established in Seattle in 1996 by medical oncologist Saul E. Rivkin MD (retired), in loving memory of his wife Marsha, who lost her life to ovarian cancer. The Rivkin Center invests in cutting-edge research to prevent, detect, and cure ovarian cancer, a deadly and under-funded disease. The Rivkin Center has funded over \$15 million in research grants worldwide. For more information, please visit www.rivkin.org or call (206)215-6200.

Release Date: September 6, 2023